Utrophin Modulator Drugs As Potential Therapies for Duchenne and Becker Muscular Dystrophies

Overview

Journal Neuropathol Appl Neurobiol

Specialty Neurology

Date 2021 May 17

PMID 33999469

Citations 17

Authors

Patricia Soblechero-Martin

Andrea Lopez-Martinez

Laura de la Puente-Ovejero

Ainara Vallejo-Illarramendi

Virginia Arechavala-Gomeza

Affiliations

Soon will be listed here.

Abstract

Utrophin is an autosomal paralogue of dystrophin, a protein whose deficit causes Duchenne and Becker muscular dystrophies (DMD/BMD). Utrophin is naturally overexpressed at the sarcolemma of mature dystrophin-deficient fibres in DMD and BMD patients as well as in the mdx Duchenne mouse model. Dystrophin and utrophin can co-localise in human foetal muscle, in the dystrophin-competent fibres from DMD/BMD carriers, and revertant fibre clusters in biopsies from DMD patients. These findings suggest that utrophin overexpression could act as a surrogate, compensating for the lack of dystrophin, and, as such, it could be used in combination with dystrophin restoration therapies. Different strategies to overexpress utrophin are currently under investigation. In recent years, many compounds have been reported to modulate utrophin expression efficiently in preclinical studies and ameliorate the dystrophic phenotype in animal models of the disease. In this manuscript, we discuss the current knowledge on utrophin protein and the different mechanisms that modulate its expression in skeletal muscle. We also include a comprehensive review of compounds proposed as utrophin regulators and, as such, potential therapeutic candidates for these muscular dystrophies.

Citing Articles

Activation of endogenous full-length utrophin by MyoAAV-UA as a therapeutic approach for Duchenne muscular dystrophy.

Wu R, Li P, Xiao P, Zhang S, Wang X, Liu J Nat Commun. 2025; 16(1):2398.

PMID: 40064877 PMC: 11894210. DOI: 10.1038/s41467-025-57831-5.

Molecular and Biochemical Therapeutic Strategies for Duchenne Muscular Dystrophy.

Krishna L, Prashant A, Kumar Y, Paneyala S, Patil S, Ramachandra S Neurol Int. 2024; 16(4):731-760.

PMID: 39051216 PMC: 11270304. DOI: 10.3390/neurolint16040055.

The Role of MicroRNA in the Pathogenesis of Duchenne Muscular Dystrophy.

Kielbowski K, Bakinowska E, Procyk G, Zietara M, Pawlik A Int J Mol Sci. 2024; 25(11).

PMID: 38892293 PMC: 11172814. DOI: 10.3390/ijms25116108.

3D-QSAR Modeling on 2-Pyrimidine Carbohydrazides as Utrophin Modulators for the Treatment of Duchenne Muscular Dystrophy by Combining CoMFA, CoMSIA, and Molecular Docking Studies.

Mahmoudzadeh Laki R, Pourbasheer E ACS Omega. 2024; 9(23):24707-24720.

PMID: 38882130 PMC: 11171099. DOI: 10.1021/acsomega.4c01225.

How Can Proteomics Help to Elucidate the Pathophysiological Crosstalk in Muscular Dystrophy and Associated Multi-System Dysfunction?.

Dowling P, Trollet C, Negroni E, Swandulla D, Ohlendieck K Proteomes. 2024; 12(1).

PMID: 38250815 PMC: 10801633. DOI: 10.3390/proteomes12010004.

References

Gregorevic P, Allen J, Minami E, Blankinship M, Haraguchi M, Meuse L . rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat Med. 2006; 12(7):787-9. PMC: 4244883. DOI: 10.1038/nm1439. View

Chen H, Chin Y, Lundy D, Liang C, Chi Y, Kuo P . Utrophin Compensates dystrophin Loss during Mouse Spermatogenesis. Sci Rep. 2017; 7(1):7372. PMC: 5547154. DOI: 10.1038/s41598-017-05993-8. View

Gilbert R, Nalbantoglu J, Petrof B, Ebihara S, Guibinga G, Tinsley J . Adenovirus-mediated utrophin gene transfer mitigates the dystrophic phenotype of mdx mouse muscles. Hum Gene Ther. 1999; 10(8):1299-310. DOI: 10.1089/10430349950017987. View

Babbs A, Chatzopoulou M, Edwards B, Squire S, Wilkinson I, Wynne G . From diagnosis to therapy in Duchenne muscular dystrophy. Biochem Soc Trans. 2020; 48(3):813-821. PMC: 7329342. DOI: 10.1042/BST20190282. View

Kennedy T, Moir L, Hemming S, Edwards B, Squire S, Davies K . Utrophin influences mitochondrial pathology and oxidative stress in dystrophic muscle. Skelet Muscle. 2017; 7(1):22. PMC: 5655821. DOI: 10.1186/s13395-017-0139-5. View

Miura P, Chakkalakal J, Boudreault L, Belanger G, Hebert R, Renaud J . Pharmacological activation of PPARbeta/delta stimulates utrophin A expression in skeletal muscle fibers and restores sarcolemmal integrity in mature mdx mice. Hum Mol Genet. 2009; 18(23):4640-9. DOI: 10.1093/hmg/ddp431. View

Vainzof M, Passos-Bueno M, Man N, Zatz M . Absence of correlation between utrophin localization and quantity and the clinical severity in Duchenne/Becker dystrophies. Am J Med Genet. 1995; 58(4):305-9. DOI: 10.1002/ajmg.1320580403. View

Hafner P, Bonati U, Klein A, Rubino D, Gocheva V, Schmidt S . Effect of Combination l-Citrulline and Metformin Treatment on Motor Function in Patients With Duchenne Muscular Dystrophy: A Randomized Clinical Trial. JAMA Netw Open. 2019; 2(10):e1914171. PMC: 6824222. DOI: 10.1001/jamanetworkopen.2019.14171. View

Krag T, Bogdanovich S, Jensen C, Fischer M, Hansen-Schwartz J, Javazon E . Heregulin ameliorates the dystrophic phenotype in mdx mice. Proc Natl Acad Sci U S A. 2004; 101(38):13856-60. PMC: 518764. DOI: 10.1073/pnas.0405972101. View

10.

Godfrey C, Desviat L, Smedsrod B, Pietri-Rouxel F, Denti M, Disterer P . Delivery is key: lessons learnt from developing splice-switching antisense therapies. EMBO Mol Med. 2017; 9(5):545-557. PMC: 5412803. DOI: 10.15252/emmm.201607199. View

11.

Blake D, Weir A, Newey S, Davies K . Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev. 2002; 82(2):291-329. DOI: 10.1152/physrev.00028.2001. View

12.

Duan D . Micro-utrophin Therapy for Duchenne Muscular Dystrophy. Mol Ther. 2019; 27(11):1872-1874. PMC: 6838911. DOI: 10.1016/j.ymthe.2019.10.011. View

13.

Soblechero-Martin P, Lopez-Martinez A, de la Puente-Ovejero L, Vallejo-Illarramendi A, Arechavala-Gomeza V . Utrophin modulator drugs as potential therapies for Duchenne and Becker muscular dystrophies. Neuropathol Appl Neurobiol. 2021; 47(6):711-723. PMC: 8518368. DOI: 10.1111/nan.12735. View

14.

Ballmann C, Denney T, Beyers R, Quindry T, Romero M, Amin R . Lifelong quercetin enrichment and cardioprotection in Mdx/Utrn+/- mice. Am J Physiol Heart Circ Physiol. 2016; 312(1):H128-H140. DOI: 10.1152/ajpheart.00552.2016. View

15.

Sengupta K, Loro E, Khurana T . PMO-based let-7c site blocking oligonucleotide (SBO) mediated utrophin upregulation in mdx mice, a therapeutic approach for Duchenne muscular dystrophy (DMD). Sci Rep. 2020; 10(1):21492. PMC: 7726560. DOI: 10.1038/s41598-020-76338-1. View

16.

Moorwood C, Khurana T . Duchenne muscular dystrophy drug discovery - the application of utrophin promoter activation screening. Expert Opin Drug Discov. 2013; 8(5):569-81. DOI: 10.1517/17460441.2013.777040. View

17.

Casper R, Quesne M, Rogers I, Shirota T, Jolivet A, Milgrom E . Resveratrol has antagonist activity on the aryl hydrocarbon receptor: implications for prevention of dioxin toxicity. Mol Pharmacol. 1999; 56(4):784-90. View

18.

Ljubicic V, Miura P, Burt M, Boudreault L, Khogali S, Lunde J . Chronic AMPK activation evokes the slow, oxidative myogenic program and triggers beneficial adaptations in mdx mouse skeletal muscle. Hum Mol Genet. 2011; 20(17):3478-93. DOI: 10.1093/hmg/ddr265. View

19.

Bulfield G, Siller W, Wight P, Moore K . X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci U S A. 1984; 81(4):1189-92. PMC: 344791. DOI: 10.1073/pnas.81.4.1189. View

20.

Sonnemann K, Heun-Johnson H, Turner A, Baltgalvis K, Lowe D, Ervasti J . Functional substitution by TAT-utrophin in dystrophin-deficient mice. PLoS Med. 2009; 6(5):e1000083. PMC: 2680620. DOI: 10.1371/journal.pmed.1000083. View